Gastroenterology News and Research

RSS

Gastroenterology is the branch of medicine where the digestive system and its disorders are studied.

Interim data from Bristol-Myers Squibb's BARACLUDE study for chronic hepatitis B patients

Bristol-Myers Squibb today announced 48-week data from an ongoing study (ETV-048) of chronic hepatitis B patients with decompensated cirrhosis, in which BARACLUDE demonstrated greater viral suppression compared to adefovir. The new BARACLUDE data were presented today at the 60th Annual Meeting of the American Association for the Study of Liver Diseases.

2 Nov 2009

Extending hepatitis C treatment for liver transplant patients results in sustained viral clearance

Extending hepatitis C treatment for liver transplant patients beyond current practice results in high rates of clearance of the hepatitis C virus from the blood, as well as a low rate of relapse, according to a Henry Ford Hospital study.

2 Nov 2009

Meeting to understand gastrointestinal problems in children with ASDs to be held

Autism Speaks, the American Academy of Pediatrics (AAP) and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) will host one of the largest gatherings of researchers, clinicians and pediatric specialists to better understand the gastrointestinal (GI) problems in children with autism spectrum disorders (ASDs).

31 Oct 2009

Data from multiple clinical and preclinical studies evaluating Hematide announced

Affymax, Inc. and Takeda Pharmaceutical Global Research & Development Center, Inc., today announced data from multiple clinical and preclinical studies evaluating Hematide, including preliminary results of a Phase 2 trial which demonstrated that Hematide increased hemoglobin levels in a group of anemic hemodialysis (HD) patients.

31 Oct 2009

P&G's global branded prescription pharmaceutical business acquired by Warner Chilcott

Warner Chilcott plc announced today it has completed the acquisition of The Procter & Gamble Company's global branded prescription pharmaceutical business. The acquisition complements Warner Chilcott's existing presence in women's health care and adds new therapeutic and geographic markets.

30 Oct 2009

Soundview Medical Associates chooses Allscripts' EHR and PM for better management

Allscripts announced today that Soundview Medical Associates has selected Allscripts Electronic Health Record (EHR) and Practice Management (PM) to enhance the quality of the care delivered by its 22 physicians, improve patient communications, and better manage the cost of care delivery.

30 Oct 2009

Cumberland Pharmaceuticals and Phebra team up to commercialize Caldolor injection

Cumberland Pharmaceuticals Inc. and Phebra Pty Ltd., an Australian-based specialty pharmaceutical company, today announced they have entered into an exclusive partnership for the commercialization of Caldolor® (ibuprofen) Injection in Australia and New Zealand.

30 Oct 2009

Ipsen announces sales highlights for the first nine months of 2009

Ipsen reported its sales for the third quarter and first nine months of 2009.

29 Oct 2009

World Journal of Gastroenterology reports a case of metallic foreign body in lower mid-abdomen

Foreign body ingestion is a frequent gastrointestinal emergency. However, long spoon swallowing is a rare event. Most swallowed spoons have been found in the stomach. Previously, there has been no reported case of a long spoon reaching the jejunum.

29 Oct 2009

Perioperative oral dietary supplements before elective surgery offers no functional benefit

Blood glucose levels in a lot of patients fed normal liquid food (NLF) and a high calorie diet (HCD) were high. There was no significant difference in the blood prealbumin levels. There was a significant increase in the blood cortisol levels in some patients. The stress of surgery may be tolerated by children by feeding up to 2 h before elective surgery.

29 Oct 2009

Study: Short-term use of COX-2 inhibitors may help prevent gastric cancer

Elevated expression of COX-2 is observed in a wide variety of human malignancies, including gastric cancer. Long-term high dose COX-2 inhibitors can inhibit gastric carcinogenesis in animal models, but the possible life-threatening cardiovascular adverse events limit its popular application. Therefore, it is important to evaluate the optimal intervention point of COX-2 inhibitors for inhibiting H. pylori-associated gastric carcinogenesis.

29 Oct 2009

CCO HIV inPractice to provide critical information for the management of HIV/AIDS launched

Clinical Care Options (CCO), a leader in the development of innovative online, print, and live medical education programs and medical education technologies for healthcare professionals, announced the launch of CCO HIV inPractice, a new, free, online point-of-care resource for clinicians that provides critical information for the management of HIV/AIDS.

29 Oct 2009

Lifestyle and genetic factors are considered to play a major role in "Asian paradox"

Although Helicobacter pylori (H. pylori) has been classified as a class I (or definite) carcinogen by World Health Organization (WHO), the controversy as to why only a minority of infected patients develop gastric cancer still remains. Moreover, in Asian countries such as Indonesia, Japan, China, and Thailand, where the H. pylori infection rates are similar, there is a significant difference regarding the outcome of gastric cancer. That fact has been termed the "Asian paradox".

29 Oct 2009

HD colonoscopy is more sensitive than standard colonoscopy in finding polyps: Study

High-definition (HD) colonoscopy is much more sensitive than standard colonoscopy in finding polyps that could morph into cancer, say researchers at the Mayo Clinic campus in Florida.

29 Oct 2009

New data from CIMZIA WELCOME trial to be presented at the ACG meeting

According to new results from the WELCOME trial, exploratory data analyzing the impact of treatment with CIMZIA(®) (certolizumab pegol) - the only PEGylated anti-TNF (alpha) (Tumor Necrosis Factor alpha) - administered either every two weeks or every four weeks, showed that the majority of Crohn's disease patients in both dosing groups experienced no hospitalizations and surgical procedures during the course of the 26-week study.

28 Oct 2009

Controlled trial in UC meets primary endpoint of non- inferiority for reducing ulcerative colitis

Results from the largest prospective controlled ulcerative colitis (UC) trial conducted to date, called the QD dosing investigation for efficacy IN UC maintenance (QDIEM), found that once-daily dosing of Asacol(R) (mesalamine) delayed-release 400 mg tablets at 1.6-2.4 g/day was comparable to twice-daily dosing for the maintenance of remission in patients with UC.

28 Oct 2009

Study of ‘real-life’ experiences of patients undergoing 5-ASA treatment for ulcerative colitis

InfoMedics, Inc., a company that engages patients and physicians to communicate better through the delivery of treatment feedback, has poster presentations at three industry conferences in October 2009. All of these studies provide a unique look at real-life patient feedback regarding experiences with medications for chronic conditions including ulcerative colitis (UC) and attention-deficit/hyperactivity disorder (ADHD) in adults and children.

28 Oct 2009

Treatment with TYSABRI reduces the rate of hospitalization in Crohn’s patients

Elan Corporation, plc and Biogen Idec today announced data showing that treatment with TYSABRI® (natalizumab) significantly reduced the rate of hospitalization compared with placebo in patients with moderate–to–severe Crohn’s disease during both induction and maintenance treatment.

28 Oct 2009

Data from Phase II clinical trial of NKTR-118 presented

Data from a phase II study demonstrated that oral NKTR-118 improved lower gastrointestinal dysfunction by increasing the frequency of bowel movements in patients with opioid-induced constipation, while simultaneously preserving opioid-mediated analgesia.

28 Oct 2009

FDA issues clearance for Lumenis' PolyScope Flexible Endoscope

Lumenis Ltd., a global developer, manufacturer and seller of laser, light-based and radiofrequency devices for surgical, aesthetic, and ophthalmic applications, announced that on September 30th, 2009 the FDA issued a 510K to Lumenis stating that the PolyScope Flexible Endoscope can now be sold in the United States.

From Lumenis Inc. 28 Oct 2009

Gastroenterology News and Research

Further Reading

Interim data from Bristol-Myers Squibb's BARACLUDE study for chronic hepatitis B patients

Extending hepatitis C treatment for liver transplant patients results in sustained viral clearance

Meeting to understand gastrointestinal problems in children with ASDs to be held

Data from multiple clinical and preclinical studies evaluating Hematide announced

P&G's global branded prescription pharmaceutical business acquired by Warner Chilcott

Soundview Medical Associates chooses Allscripts' EHR and PM for better management

Cumberland Pharmaceuticals and Phebra team up to commercialize Caldolor injection

Ipsen announces sales highlights for the first nine months of 2009

World Journal of Gastroenterology reports a case of metallic foreign body in lower mid-abdomen

Perioperative oral dietary supplements before elective surgery offers no functional benefit

Study: Short-term use of COX-2 inhibitors may help prevent gastric cancer

CCO HIV inPractice to provide critical information for the management of HIV/AIDS launched

Lifestyle and genetic factors are considered to play a major role in "Asian paradox"

HD colonoscopy is more sensitive than standard colonoscopy in finding polyps: Study

New data from CIMZIA WELCOME trial to be presented at the ACG meeting

Controlled trial in UC meets primary endpoint of non- inferiority for reducing ulcerative colitis

Study of ‘real-life’ experiences of patients undergoing 5-ASA treatment for ulcerative colitis

Treatment with TYSABRI reduces the rate of hospitalization in Crohn’s patients

Data from Phase II clinical trial of NKTR-118 presented

FDA issues clearance for Lumenis' PolyScope Flexible Endoscope

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News